文献速递泌尿生殖腹部MR

多参数MRI评估肌层浸润性膀胱癌新辅助治疗后残留肿瘤:指导膀胱保留的可靠工具

Multiparametric MRI for assessing residual tumors in patients with muscle-invasive bladder cancer after neoadjuvant treatment: a reliable tool for guiding bladder preservation.
PubMed 文献 · Eur Radiol · 2025-06-30

这项双中心队列研究纳入149例肌层浸润性膀胱癌患者,评估新辅助治疗后多参数MRI区分病理分期ypT0与ypT1-4的临床效用。增强MRI预测ypT0的AUC为0.84,优于T2DWI的0.75(p=0.002),两种方案观察者间一致性均优秀。增强MRI在识别新辅助治疗后ypT0状态方面准确性更优,可作为指导膀胱保留决策的重要诊断工具。

要点

  • 增强MRI预测新辅助治疗后ypT0的AUC为0.84,优于T2DWI的0.75(p=0.002)。
  • T2DWI与增强MRI观察者间一致性均优秀(κ=0.89与κ=0.85)。
  • 增强MRI是检测新辅助治疗后完全肿瘤缓解的可靠无创方法。

核心结论

  • 多参数MRI,尤其是增强MRI,在识别肌层浸润性膀胱癌新辅助治疗后ypT0状态方面准确性更优。
  • 增强MRI可作为指导膀胱保留临床决策的重要诊断工具。

研究设计与样本

  • 双中心队列研究,纳入149例患者(平均年龄62岁±10[SD],131例男性),来自两家机构。
  • 分析所有连续接受新辅助治疗后手术患者的治疗后多参数MRI。
  • 两名经验丰富的放射科医生独立评估新辅助治疗后MRI特征,基于T2加权扩散加权成像(T2DWI)和增强MRI扫描分别判定治疗后yT分期。
  • 评估两种方案区分治疗后ypT0与ypT1-4肿瘤的诊断准确性,采用Cohen kappa统计量评价观察者间一致性。

诊断标准与关键数值

  • 增强MRI方案预测治疗后ypT0的AUC为0.84(95%CI:0.77,0.91),优于T2DWI方案的0.75(95%CI:0.67,0.81;p=0.002)。
  • T2DWI方案观察者间一致性κ=0.89,增强MRI方案κ=0.85,均优秀。
  • 治疗后yT分期分别基于T2DWI和增强MRI扫描判定,用于区分ypT0与ypT1-4。

临床应用与阅片要点

  • 增强MRI可用于检测肌层浸润性膀胱癌新辅助治疗后的完全肿瘤缓解,帮助筛选适合膀胱保留策略的患者。
  • 增强MRI预测ypT0的准确性优于T2DWI,阅片时可将增强MRI作为评估治疗后残留肿瘤的重点方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the clinical utility of multiparametric MRI in differentiating pathological stages (ypT0 vs ypT1-4) in patients with muscle-invasive bladder cancer (MIBCa) following neoadjuvant therapy (NAT).

MATERIALS AND METHODS: In this double-center cohort study, post-NAT multiparametric MRI in all consecutive patients who underwent surgery after NAT was analyzed. Two experienced radiologists independently evaluated the MRI features obtained after NAT. The post-NAT yT stage was assigned based on T2-weighted diffusion-weighted imaging (T2DWI) and on contrast-enhanced MRI scans. The diagnostic accuracies for distinguishing post-NAT ypT0 from ypT1-4 tumors with the two protocols were evaluated. Cohen's kappa (κ) statistics were used to evaluate the consistency between readers for the post-NAT yT stage.

RESULTS: A total of 149 patients (mean age, 62 years ± 10 [SD]; 131 men) from two institutions were enrolled. The area under the receiver operating characteristic curve of the contrast-enhanced MRI protocol in predicting post-NAT ypT0 stage was 0.84 (95% CI: 0.77, 0.91), which was better than that of the T2DWI protocol (0.75; 95% CI: 0.67, 0.81; p = 0.002). The interobserver agreement was excellent for both the T2DWI protocol (κ = 0.89) and the contrast-enhanced MRI protocol (κ = 0.85).

CONCLUSIONS: Multiparametric MRI, particularly contrast-enhanced MRI, demonstrated superior accuracy in identifying ypT0 status following NAT in MIBCa, establishing it as an essential diagnostic tool for guiding bladder preservation in clinical decision-making.

KEY POINTS: Question Accurately identifying pathological complete response (ypT0) after NAT is essential for selecting bladder-preservation strategies, yet remains clinically challenging. Findings Post-treatment contrast-enhanced MRI accurately identified ypT0 status with an AUC of 0.84 and excellent inter-reader agreement, outperforming T2DWI. Clinical relevance Contrast-enhanced MRI is a reliable, non-invasive method for detecting complete tumor response after NAT, enabling better patient selection for bladder-sparing approaches and potentially improving quality of life.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Cai Q, Tian L, Kong L, et al. Multiparametric MRI for assessing residual tumors in patients with muscle-invasive bladder cancer after neoadjuvant treatment: a reliable tool for guiding bladder preservation. Eur Radiol. 2025. PMID: 40586817. doi:10.1007/s00330-025-11773-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。